First Tracks Biotherapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| TRAX | CLYM | 8SJ.F | LKFT | ANNX | ABCL | |
|---|---|---|---|---|---|---|
| Market cap | 2.06B | 535.88M | 1.84B | 2.25B | 820.88M | 3.98B |
| P/E (TTM) | — | — | — | 3.2 | — | — |
| Forward P/E | -13.6 | -9.3 | — | -28.6 | -4.0 | -16.1 |
| Price/book | 10.3 | 2.2 | 2.4 | 12.2 | 4.1 | 4.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +143.89% | +407.81% | −37.59% | +9.26% | +43.38% | +171.08% |
| Today | +5.83% | −4.31% | +1.70% | +6.03% | +3.34% | +0.82% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All TRAX news ›First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
The Manila Times SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways
First Tracks Biotherapeutics (NASDAQ:TRAX) Hits New 52-Week High on Strong Earnings
Posted by Michael Walen on Nov 4th, 2026 First Tracks Biotherapeutics (NASDAQ:TRAX – Get Free Report) shares hit a new 52-week high during mid-day trading on Wednesday following a stronger than expected earnings report. The company traded…
CELIA Staking Dashboard Due in Days as Lia Labs Faces Trust Test
The @Celia_Token post adds two points. Updates on development, exchange listings, and milestones will appear on that account. $CELIA remains the first official product token in the @Lia_Labs ecosystem. The update gives no launch date,…
How CUE-221’s Phase 2 Results In CSU Could Translate To Food Allergy
The “dual-mechanism” anti-IgE antibody CUE-221 has delivered encouraging phase 2 results in chronic spontaneous urticaria. Could it separate from omalizumab and ozureprubart in food allergy? Kuo et al. proposed the CD23 mechanism on the…
argenx's Forte acquisition delivers coeliac trial win
argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2 billion acquisition of Forte Biosciences, will move into phase 3 development for coeliac disease after showing efficacy in a mid-stage trial. There are no FDA-approved…
Guggenheim Initiates Faeth Therapeutics at Buy With $70 Price Target
Faeth Therapeutics has an average rating of buy and mean price target of $56.67, according to analysts polled by FactSet. ... Biotechnology & Medical Research Guggenheim Initiates Faeth Therapeutics at Buy With $70 Price Target Published…
First Tracks Biotherapeutics (TRAX) - What Are Investment Firms Thinking About This Stock?
View Our Latest Stock Analysis on TRAX NASDAQ TRAX opened at $36.28 on Tuesday. The business's fifty day moving average price is $38.92. The company has a market cap of $1.30 billion and a P/E ratio of -19.72. First Tracks Biotherapeutics…
Celiac Disease Foundation Launches Venture Fund to Transform the Future of Celiac Disease
Mar 18, 2026, 10:20 ET Managed in partnership with Triple G Ventures, the Impact Fund will invest in scalable innovations across early detection, prevention, education, awareness, and breakthrough therapies. By combining mission-driven…
News from Celiac Disease Foundation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.
news News from Celiac Disease Foundation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. 08:25 ET How…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- theglobeandmail.com4
- globenewswire.com3
- stocktitan.net3
- manilatimes.net2
- marketbeat.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 25 articles, not a forecast.